<DOC>
	<DOCNO>NCT01048333</DOCNO>
	<brief_summary>- Primary objective evaluate time onset effect formoterol , 9 μg single dose , compare salmeterol , 50 μg single dose , patient moderate COPD.Forced Expiratory Volume 1 second ( FEV1 ) measure spirometry 5 minute postdose . - Secondary efficacy variable : Average FEV1 first 15 minute ( area FEV1 curve 0 15 minute ) , Average FEV1 120 minute ( area FEV1 curve 0 120 minute )</brief_summary>
	<brief_title>Evaluate Onset Effect Patients With Chronic Obstructive Pulmonary Disease ( COPD ) Treated With Formoterol Turbuhaler®</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>A clinical diagnosis COPD accord GOLD guideline , current COPD symptoms A current previous smoke history equivalent 10 pack per year ( 1 pack year = 20 cigarette smoke per day one year ) . Documented use shortacting inhaled bronchodilator ( β2agonist anticholinergic ) reliever medication . A history and/or current diagnosis asthma . Patients experience COPD exacerbation require hospitalisation and/or course antibiotic and/or course systemic steroid within 30 day ( end exacerbation treatment ) prior Visit 1 and/or runin period . A history and/or current diagnosis atopic diseases allergic rhinitis eczema age 40 .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Chronic Obstructive Pulmonary Disease</keyword>
	<keyword>Onset effect</keyword>
	<keyword>COPD</keyword>
	<keyword>Oxis Turbuhaler</keyword>
</DOC>